Castle Biosciences, Inc. (CSTL)

USD 26.52

(-5.76%)

Market Cap (In USD)

742.75 Million

Revenue (In USD)

219.78 Million

Net Income (In USD)

-57.46 Million

Avg. Volume

424.25 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
16.965-35.84
PE
-
EPS
-
Beta Value
0.985
ISIN
US14843C1053
CUSIP
14843C105
CIK
1447362
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Derek J. Maetzold
Employee Count
-
Website
https://castlebiosciences.com
Ipo Date
2019-07-25
Details
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.